298.64MMarket Cap-2.14P/E (TTM)
7.2200High6.7000Low617.83KVolume7.1200Open7.2300Pre Close4.26MTurnover2.28%Turnover RatioLossP/E (Static)44.51MShares13.520052wk High26.95P/B182.11MFloat Cap2.100052wk Low--Dividend TTM27.14MShs Float225.8400Historical High--Div YieldTTM7.19%Amplitude2.1000Historical Low6.8900Avg Price1Lot Size
Verastem Stock Forum
Can This New Ovarian Cancer Drug Transform Treatment? Key Data Reveals Breakthrough Potential
Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers
Thursday, 23rd January at 7:30 am
Avutometinib plus defactinib granted priority review by FDA, under the accelerated approval pathway, for recurrent KRAS mutant LGSOC; PDUFA action date set for June 30, 2025
Potential U.S. commercial launch in recurrent KRAS mutant LGSOC planned for mid-2025
RAMP 205 trial in 1L metastatic pancreatic cancer cont...
Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China
Tuesday, 14th January at 7:30 am
VS-7375 is a potential best-in-class oral and selective KRAS G12D (ON/OFF) inhibitor currently in Phase 1 development in China in advanced KRAS G12D mutant solid tumors; Verastem anticipates filing a U.S. IND application for VS-7375 during Q1 2025 a...
Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025
Monday, 13th January at 7:30 am
Company cash, cash equivalents, and investments of $88.8 million as of December 31, 2024; pro forma cash position of $128.6 million including debt refinancing and equity issuance provides cash runway beyond FDA approval
Veras...
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review
Big News came out
No comment yet